- Home
- SRG vs FATE Comparison
SRG vs FATE Comparison
Compare SRG & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRG | FATE |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | United States |
| Employees | 5 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.4M | 125.6M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | SRG | FATE |
|---|---|---|
| Price | $2.55 | $2.85 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.10 |
| AVG Volume (30 Days) | 173.6K | ★ 4.9M |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.88 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,646,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.31 | $0.91 |
| 52 Week High | $4.56 | $3.23 |
Technical Indicators
Market Signals| Indicator | SRG | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 41.79 | 56.89 |
| Support Level | $2.43 | $1.01 |
| Resistance Level | $2.74 | $2.88 |
| Average True Range (ATR) | 0.09 | 0.26 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 16.28 | 36.51 |
Price Performance
Historical ComparisonAbout SRG Seritage Growth Properties
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management, sale, and leasing of diversified retail and mixed-use properties throughout the United States.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.